Introduction
Fatty acids are major constituents of cellular membranes acting as a substrate reservoir for the formation of bioactive lipid metabolites and influencing the environment of membrane proteins . Many metabolites are formed by enzymatic metabolism in what is known as the arachidonic acid cascade. Arachidonic acid (ARA) is a long-chain omega-6 polyunsaturated fatty acid (PUFA) and a substrate of cyclooxygenase and lipoxygenase enzymes. These enzymes form prostaglandins and leukotrienes, respectively, the majority of which have proinflammatory activity (Funk, 2001; Haeggstrom and Funk, 2011) . Cytochrome P450 (CYP450) monoepoxygenase metabolism of PUFAs is a third, less studied pathway of the ARA cascade (Capdevila et al., 1992) . CYP450 activity forms regioisomers of epoxy fatty acids (EpFAs) from the parent PUFAs (Spector, 2009 ). However, EpFAs are quickly transformed by the soluble epoxide hydrolase (sEH) enzyme which metabolizes them to their corresponding vicinal diols (Spector et al., 2004) . The EpFA metabolites of ARA, epoxyeicosatrienoic acids (EETs), are antihyperalgesic in acute inflammatory pain and chronic neuropathy models (Inceoglu et al., , 2008 (Inceoglu et al., , 2012 . The diol products of EETs metabolism, dihydroxyeicosatrienoic acids (DiHETs), lack this activity in numerous in vivo models (Zeldin, 2001) . Small molecule inhibitors of the sEH enzyme (sEHI) have been developed and optimized for in vivo administration. The sEHI block the metabolism of EpFA into diols and stabilize the concentrations of these beneficial bioactive mediators (Inceoglu et al., 2012) . The cascade was named for ARA metabolism, but it is now clear that other PUFA including omega-3 docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are also substrates for these enzymes (Schmitz and Ecker, 2008) . DHA and EPA are metabolized via CYPP450s into multiple regioisomers of epoxydocosapentaenoic acids (EDPs) and eicosatetraenoic acids (EEQs), respectively, which are further metabolized by sEH into their corresponding diols (Fer et al., 2008; Morisseau et al., 2010; Konkel and Schunck, 2011) . Docosahexaenoic acid is the predominant fatty acid in the central nervous system (CNS) with concentrations reaching 20-50% of fatty acids in the brain (Burdge, 2004) . DHA is essential to CNS development and normal brain functioning in adults (Uauy and Mena, 2001) . DHA also effects nociceptive signalling by lowering pain in inflammatory conditions including rheumatoid arthritis (Kremer, 2000) and inflammatory bowel disease (Belluzzi et al., 2000) . In addition, DHA blocked acetic acid writhing and formalin-induced pain in murine models (Nakamoto et al., 2010; Nobre et al., 2013) . A recent study suggests DHA indirectly affects opioid signalling via modulating the release of endogenous opioid peptides . CYPP450 metabolites have also demonstrated activity via opioid system mechanisms (Conroy et al., 2010 (Conroy et al., , 2013 . Importantly, the EpFA of DHA and EPA were ≥100-fold more potent than their parent PUFAs suggesting that the antihyperalgesia of the PUFAs is likely due to their epoxide metabolites ). Here, we tested our primary hypothesis that epoxidized metabolites are mediating analgesia in neuropathic pain models and a secondary hypothesis that this action involves but is not restricted to opioid system signalling.
Materials and methods

Animals
All procedures and animal care included in these experiments adhered to the guidelines of the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and were performed in accordance with protocols approved by the Animal Use and Care Committee (IACUC) of the University of California, Davis. Great care was taken to minimize suffering of the animals and to reduce the number of animals used. Experiments on sEH knockout mice used mice on a 129X1/SvJ C57BL/6 background, backcrossed over 10 generations with targeted disruption of the EPHX2 gene and maintained at the facilities of the University of California, Davis (Sinal et al., 2000) . The EPHX2 strain of mice was maintained as heterozygous animals with knockout and control animals obtained from a backcross followed by genotyping. All other experiments on wild-type mice used groups of male C57BL/6 mice (20-22 g) purchased from Charles River Laboratories. Both wild-type and sEH null mice were housed under standard conditions (25°C) in a fixed 12-h light/ dark cycle with ad libitum food and water.
Chemicals
The sEH inhibitor t-TUCB: trans-4-[4-(3-trifluoromethoxyphenyl-l-ureido)-cyclohexyloxy]-benzoic acid (also referred to as UC1728) and TPPU: 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (UC1770) were synthesized in house and characterized as previously described (Hwang et al., 2007; Liu et al., 2009; Rose et al., 2010) . t-TUCB and TPPU were prepared immediately before use in PEG400 and subcutaneously administered to mice in a 50 lL volume. The EDP mixture was a regioisomeric mixture of the methyl esters of epoxidized DHA synthesized in house per previously described methods . The EDP mixture was formulated in 7% ethyl alcohol in miglyol and injected subcutaneously and the ratio of regioisomers given in the Supporting Information Fig. S1 was analysed per previously published methods (Yang et al., 2009 ). Celecoxib was formulated in PEG400 and naloxone (Sigma-Aldrich, St Louis, MO, USA) was formulated in saline and both injected subcutaneously in a 50 lL volume.
Behavioral assays
All groups of mice were allowed to acclimate for a minimum of 3 days and then were assessed for their na€ ıve mechanical threshold baseline scores. Streptozocin treatment with 150 mg/kg i.p. streptozocin (Davidson et al., 2009 ) results in robust hyperglycaemia in mice. Several overt phenotypic phenomena of streptozocin-induced diabetes were observed in the mice but not quantified including polyuria, poor grooming and ataxia. All included groups of mice were assessed phenotypically and for allodynia with an electronic aesthesiometer in the von Frey assay. Allodynia is the sensing of pain from innocuous stimuli that is a hallmark of diabetic neuropathy and is assessed in the model with grams of force to elicit a hind paw withdrawal. The diabetic state was then further confirmed with blood glucose monitoring. The glucose levels averaged from 378 mg/dL among included groups, however, all included mice had levels >250 mg/dL and were considered diabetic. The sEH knockout mice become equally hyperglycaemic with average blood glucose of >270 mg/dL. After the induction of diabetes all groups were assessed for their diabetic mechanical withdrawal thresholds. Allodynia was indicated by a >30% decrease in withdrawal compared to pre-diabetic baseline values and was assessed and quantified in the mice using an electronic von Frey aesthesiometer (IITC, Woodland Hills, CA, USA). For the von Frey assay mice were first acclimated to the clear acrylic chambers on a steel mesh floor. Then the mouse hind paw was probed through the mesh with a rigid tip probe to measure the grams of force required to elicit a hind paw withdrawal. Mechanical withdrawal thresholds (MWT) were measured a minimum of 3 times per mouse in all groups and calculated as the mean AE SEM for a group of mice tested on the same day under the same conditions. The mean MWT for groups are reported as pre-streptozocin baseline scores (Naive) and post-streptozocin painful baseline scores (Diabetic) prior to the start of treatment in the CPP in the figures. MWTs for the mice post-diabetes averaged a 45% decline in threshold baseline indicating allodynia. Similar results were observed for the sEH null mice groups with decreases in MWT (51% decline).
The conditioned place preference (CPP) assay used an apparatus as previously described (Wagner et al., 2014b) . Briefly, the apparatus is a 30 9 16 9 20 cm rectangular acrylic box with distinct visual patterns and a floor with tactilely distinct sides of equal size. The CPP assay was conducted 10 days post-streptozocin administration and after diabetic baseline allodynia was assessed with the von Frey assay. For the CPP, mice are habituated to the open box for 30 min sessions at the same time of the day on 2 consecutive days. Then on day 1 pre-conditioning preference is assessed by placing mice in the apparatus with access to both chambers and observing them for 30 min. This is followed by 3 conditioning days where the vehicle is counterbalanced daily with the compounds each for 30 min intervals. For conditioning mice receive vehicle and are immediately isolated to one chamber in the morning. At least 4 hours after the vehicle, the same mouse is treated with sEH inhibitor or drug and immediately isolated to the counterbalanced chamber. On the next (5th) day, mice are tested drug free for their preference with access to both chambers and observed for 30 min. The recorded test periods are quantified with tracking software and the results are calculated as test minus preconditioning time in the drug paired chamber. The results are represented in the figures as the change in time (Time (seconds), y axis) in the drug paired chamber. Increased time spent in a chamber (e.g. increased time in the drug paired chamber) indicated preference for that chamber. The vehicle control group received PEG400 counterbalanced to the non-preferred chamber at least 4 h after saline injection and placement in the preferred chamber. Earlier tests revealed no difference in PEG400, PEG300 or saline injections compared to na€ ıve mice.
Statistics
The nociceptive assays were evaluated with a oneway analysis of variance or t-test where appropriate. ANOVA Post hoc analysis included Holms-Sidak and Dunn's analysis as indicated with p < 0.05 considered statistically significant. Statistics were computed using commercial statistical software (Systat Software, Inc., Chicago IL, USA).
Results
EDPs mediate analgesia in neuropathic pain
Given published reports that DHA can reduce pain (Nakamoto et al., 2010 as well as published Wagner et al., 2014a ) and unpublished studies from this laboratory in other pain models we tested the hypothesis that this analgesic activity was due at least in part to the action of epoxidized DHA metabolites, the EDPs. For this we used an exogenous administration of a regioisomeric mixture of EDPs and assessed it for the ability to induce a CPP response in neuropathic mice (Fig. 1) . The EDPs are rapidly metabolized in vivo and did not induce a CPP response as a single administration. Therefore, we combined EDPs with a low dose of the t-TUCB which was previously determined to have no significant effect as a single administration in this system (Wagner et al., 2014b) . The combination of exogenous EDPs with 1 mg/kg t-TUCB significantly induced a CPP response when compared to the EDP alone and vehicle (one-way ANOVA, Holms-Sidak method, p = 0.041, n = 4-7). Although the EDPs are rapidly transformed, the absence of CPP response induced by a low 1 mg/kg dose of t-TUCB (Supporting Information Fig. S3A ) when compared to the EDP + t-TUCB combination at the same dose suggests the EDPs are mediating the analgesia and importantly in a chronic pain model. The EDPs lacked significant effect in na€ ıve mice at the same 1 mg/kg dose (Supporting Information Fig. S3B ).
3.2 Antagonism of the Mu-opioid receptor blocks EDP and sEHI-mediated analgesia in the CPP assay
When the mu-opioid receptor antagonist naloxone was tested as a single administration in diabetic neuropathic mice there was no significant effect of the compound. The administration of EDP + t-TUCB (repeated from Fig. 1 ) produced a CPP response indicating pain relief. This was blocked by the coadministration of naloxone. To support this result we also tested t-TUCB in neuropathic mice, the sEHI at 10 mg/kg was significantly analgesic against the induced diabetic neuropathy (Fig. 2 ). This robust analgesia was equally antagonized by co-administration of naloxone returning scores to control levels (one-way ANOVA, Holms-Sidak method, p = 0.001, n = 4-8).
sEH null mice with induced diabetic neuropathy do not respond to sEHI
We then tested both t-TUCB and a structurally different sEHI that has the same pharmacophore TPPU in sEH null mice that were rendered diabetic with streptozocin similar to the wild-type mice (Fig. 3) . The same dose of the t-TUCB that elicited a robust CPP in wild-type neuropathic mice did not elicit a significant response in sEH null diabetic mice (oneway ANOVA, p = 0.333, n = 7-8). There was a positive trend with t-TUCB, but the result was not statistically significant. The second sEHI TPPU was without any effect. The results of sEHI administration in the diabetic null mice support both that the sEHI-mediated analgesia occurs via targeting the sEH enzyme and the efficacy is not related to rewardbased mechanisms.
sEHI mediate effective analgesia in neuropathic pain compared to coxibs
We used the structurally distinct sEHI TPPU in the same testing paradigm to interrogate the analgesia mediated by t-TUCB and to compare with celecoxib (Fig. 4) . TPPU at the same 10 mg/kg dose used in diabetic sEH null mice had no effect in na€ ıve mice (one-way ANOVA, p = 0.132, n = 6-8). Celecoxib at the same dose seemed to induce a CPP, but the effects were not statistically significant. This corresponds to literature describing other drugs of this Figure 1 Epoxydocosapentanoic acids (EDP), the omega-3 DHAderived epoxidized metabolites, mediate analgesia in a model of diabetic neuropathic pain. Exogenous EDPs 1 mg/kg combined with an ineffective low dose of t-TUCB 1 mg/kg to block their rapid degradation by the sEH enzyme were significantly effective against neuropathic pain (t-TUCB 1 mg/kg alone appears in supplemental material). In the CPP assay this is indicated by increased time (seconds, y axis) spent in the drug paired chamber (one-way ANOVA, p = 0.041). Prior to the CPP assay diabetic mice were assessed for phenotypic allodynia indicating diabetic neuropathy in the von Frey assay. The results depicted below the graph are the grams of force to elicit a hind paw withdrawal (von Frey (gr)) of pre-streptozocin baseline scores (Na€ ıve) and post-streptozocin painful baseline scores (Diabetic) prior to the start of treatment in the CPP assay.
class inducing a CPP response (Fattore et al., 2000) . The current results in diabetic mice support an often observed lack of efficacy of non-steroidal antiinflammatory drugs on neuropathic pain in humans and animal models (Gore et al., 2007; Wagner et al., 2013; Mendlik and Uritsky, 2015) . DHA has recently demonstrated effects in diabetic pain models often attributed to its anti-inflammatory activity (Heng et al., 2015; Li et al., 2015) . However, if chronic neuropathy were treated by anti-inflammatory action alone, we would have expected celecoxib to have an antihyperalgesic effect which was not the case, although both the EDPs and the sEHI were efficacious against the neuropathic pain. However, when TPPU was tested in diabetic neuropathic mice there was a robust and significant effect indicating analgesia (one-way ANOVA, Holms-Sidak method, p = 0.003, n = 6-8). In earlier studies, TPPU in mice displayed favourable pharmacokinetics properties, although it took several days to reach a steady-state concentration via drinking water at a much lower dose than used here (Ulu et al., 2012) . The results obtained with these experiments using the CPP testing paradigm for both sEHI demonstrate the analgesia is due to targeting and inhibiting the sEH enzyme.
Discussion
With these experiments we tested several hypotheses regarding EpFA-mediated analgesia against chronic pain. We used the CPP assay which is more able to assess the tonicity of chronic pain (Davoody et al., 2011; Felice et al., 2013) and therefore the results may be more translatable to human clinical conditions. The CPP is also operant and eliminates expectation bias (Navratilova and Porreca, 2014) and misinterpretation of motor skill decrement and sedation as analgesia as with evoked responses. Furthermore, it enables examination of rewarding effects (abuse potential) in control animals.
We first tested the hypothesis that EpFAs mediate analgesia and are responsible for the effects of parent Figure 2 Analgesia mediated by EDPs and sEHI is blocked mu-opioid antagonism. The analgesia mediated by 1 mg/kg EDPs co-administered with low dose 1 mg/kg t-TUCB was blocked by naloxone (1 mg/kg) a mu-opioid receptor antagonist. The sEH inhibitor t-TUCB blocks the degradation of multiple classes of EpFA in vivo and a single administration of 10 mg/kg dose effectively induced a CPP response indicating pain relief (one-way ANOVA, p ≤ 0.001). In the CPP assay this is indicated by increased time (seconds, y axis) spent in the drug paired chamber. The efficacy of 10 mg/kg t-TUCB was also blocked by naloxone. There was no significant effect of the naloxone in control neuropathic mice. The diabetic mice were assessed for phenotypic allodynia indicating diabetic neuropathy in the von Frey assay prior to the CPP assay. The results depicted below the graph are the grams of force to elicit a hind paw withdrawal (von Frey (gr)) of pre-streptozocin baseline scores (Na€ ıve) and post-streptozocin painful baseline scores (Diabetic) prior to the start of treatment in the CPP assay. Figure 3 Inhibitors of sEH do not significantly induce a CPP response in diabetic sEH null mice. In sEH null mice induced with diabetic neuropathy neither t-TUCB nor TPPU, a structurally distinct but similarly potent sEHI, have a significant effect in the CPP assay (one-way ANOVA, p = 0.333). In the CPP assay this is measured by increased time (seconds, y axis) spent in the drug paired chamber. This is in contrast to the robust effect of t-TUCB in wild-type diabetic mice (Fig. 2) indicating that targeting the sEH enzyme mediates the sEHI efficacy. The diabetic mice were assessed for phenotypic allodynia indicating diabetic neuropathy in the von Frey assay prior to the CPP assay. The results depicted below the graph are the grams of force to elicit a hind paw withdrawal (von Frey (gr)) of pre-streptozocin baseline scores (Na€ ıve) and post-streptozocin painful baseline scores (Diabetic) prior to the start of treatment in the CPP assay.
PUFAs by administering EDPs to neuropathic mice. There is considerable evidence describing the health benefits and biological functions of DHA including antinociceptive effects. DHA attenuates loss of nerve conduction velocity and nerve blood flow in diabetic rats (Pitel et al., 2007) , acetic acid writhing and formalin-induced pain in mice (Nakamoto et al., 2010) and spinal cord injury pain in rats (Figueroa et al., 2013) . Inhibiting sEH in vivo has been successful in reducing diabetic neuropathy in rats, indicative of EpFA activity (Inceoglu et al., 2012; Wagner et al., 2013) . The EpFAs also previously blocked allodynia in neuropathic mice demonstrating direct application of the metabolites is antinociceptive (Wagner et al., 2014b) . Interestingly, EDPs appear to be a more efficacious class of EpFA in modelled inflammatory pain and most of the EDPs, with the exception of the 19,20 EDP regioisomer, are also preferred substrates of sEH . Here, we demonstrated that EDPs are analgesic against the tonic pain of diabetic neuropathy. The low-dose t-TUCB combined with the EDPs to block their transformation to diol metabolites was ineffective as a single administration (Supporting Information Fig. S3A) indicating EDPs mediate the analgesia. We tested several doses and routes of administration for EDPs or enriched DHA oil (Supporting Information Fig. S3B ) and found stabilizing EDPs with sEHI the most effective approach. There was a more robust CPP response to the sEHI than the EDPs alone suggesting that EDPs are rapidly metabolized and absent sEHI stabilization have limited effect in this assay (Supporting Information Fig. S3B ). The results indicate that sEH inhibition may be a better pharmaceutical strategy than EDPs because sEHI stabilize multiple classes of EpFAs all of which may contribute to the analgesic response.
Mu-opioid receptors (MOR) are the target of endogenous opioid peptides including beta-endorphin, Met-and Leu-enkephalin, and to a limited extent dynorphin (Pasternak and Pan, 2013) . They are also the primary route of analgesia produced by opioids such as morphine. Recently, DHA-mediated analgesia was reversed by MOR antagonists in the late-stage formalin test in mouse (Nakamoto et al., 2010) and in diabetic neuropathy in rat (Nakamoto et al., 2010; Heng et al., 2015) . However, DHA was found not to bind opioid receptors directly but to influence beta-endorphin release . Given the lack of mechanistic knowledge regarding the antinociceptive activity of PUFAs, it remains possible that EpFA are mediating these effects. Evidence supporting this hypothesis includes transgenic mice with neuron-specific deletion of Figure 4 The sEHI effectively mediates analgesia in neuropathic pain and outperforms celecoxib. (A) When the sEHI TPPU at 10 mg/kg was tested in na€ ıve mice it had no significant effect in the CPP assay. The same 10 mg/kg dose of celecoxib seemed to induce a response but it was not significant (one-way ANOVA, p = 0.132). In the CPP assay this is indicated by increased time (seconds, y axis) spent in the drug paired chamber. (B) When assessed in diabetic neuropathic mice, the 10 mg/kg TPPU showed a significant and robust response and celecoxib was without effect (oneway ANOVA, p = 0.003). The diabetic mice were assessed for phenotypic allodynia indicating diabetic neuropathy in the von Frey assay. The results depicted below the graph (where applicable) are the grams of force to elicit a hind paw withdrawal (von Frey (gr)) of pre-streptozocin baseline scores (Na€ ıve) and post-streptozocin painful baseline scores (Diabetic) prior to the start of treatment in the CPP assay. CYP450 reductase (CYP450r) which among many effects blocks EpFA formation. Mutant CYP450r mice responded normally to painful stimuli but had deficits in antinociceptive responses to morphine (Conroy et al., 2010) . In the same study intracerebroventricular administration of CYP450 inhibitors blocked morphine analgesia. More recently, site-specific MOR antagonism in wild type versus CYP450r mutants revealed attenuation of pain responses in the deficient mice (Hough et al., 2015) . Furthermore, sEH inhibition increases endogenous EpFAs and is antinociceptive (Inceoglu et al., 2012; Wagner et al., 2013) . Based on this evidence we tested if MOR antagonism blocks analgesia produced by CYP450-derived EDPs or sEHI which stabilize them. The MOR antagonist naloxone had no significant effect in control mice, although aversion has been observed by others (Sakoori and Murphy, 2008) . However, naloxone blocked the analgesia from the EDP + t-TUCB combination and also the robust CPP response to 10 mg/kg t-TUCB (Fig. 2) . Naloxone is not completely selective, but its action here does suggest there is an effect at least in part via opioid signalling. The value of opioids for chronic pain conditions is debated (Dellemijn, 1999) . Despite this, opioids are still sometimes prescribed for chronic pain and it is more often safety issues that limit their use (Moulin et al., 2007) . Given the analgesia mediated by the EDPs and sEHI and the antagonism by naloxone, it might be anticipated that the sEHI elicit side effects similar to MOR agonists. Our experiments demonstrate that EpFA are analgesic in the absence of rewarding side effects (abuse potential). The lack of addictive behaviour with sEHI discussed below and the high efficacy of sEHI in neuropathic pain models suggest that sEHI are not acting simply as opioids. In addition, experiments with CYP450r-deficient mice demonstrated that EpFA-mediated analgesia lacked MOR agonist side effects of respiratory depression, constipation and hyperlocomotion (Hough et al., 2014) .
We explored the different CPP results between sEHI and EDPs by examining if the sEHI outcome was compound related or elicited narcotic side effects by testing a second potent sEHI in the model (Fig. 4A and B) . TPPU 10 mg/kg lacked effect in control mice but was robustly effective against neuropathic pain. We also tested both inhibitors in sEH null mice induced with diabetic neuropathy and neither sEHI elicited a significant effect (Fig. 3) . A lack of rewarding effect was previously demonstrated in non-diabetic sEH null mice (Wagner et al., 2014b) . The absence of reward of two structurally different sEHI and the absence of analgesic responses in neuropathic sEH null mice supports the previous observations that inhibiting the sEH target mediates the analgesia while lacking off-target side effects. The lack of reward is interesting given the pronounced analgesia sEHI elicit as well as its antagonism with naloxone. Notably, there is evidence of cyclooxygenase and lipoxygenase inhibitors modulating opioid signalling, although neither have strong reward side effects (Vaughan et al., 1997) . Thus, the action of CYP450 products is distinct from MOR agonists because both the analgesic and side effects of opioids result from binding the receptor (Kieffer, 2000) .
There are alternative mechanisms of action for the analgesia mediated by EpFAs such as the descending modulation of pain. EpFAs in the ventrolateral periaqueductal gray (PAG) region modulate the analgesic actions of morphine and endogenous opioid peptides that act on the descending analgesic pathway (Conroy et al., 2010) . There is GABA modulation by EpFA and sEHI and therefore possible GABA interaction with the descending modulation of pain. GABA interneurons in the PAG or raphe magnus modulate the enkephalin sensitive neurons in these areas which may be subject to opioid receptor antagonism (Garcia-Larrea and Peyron, 2007) . Additional evidence points to CYP450 inhibitors active at a point of convergence for opioid and non-opioid analgesics downstream of opioid receptors (Heinricher et al., 2010) . Super-perfusion of ARA to rat PAG decreased GABAergic postsynaptic currents (Vaughan et al., 1997) . This effect was hypothesized to depend on ARA metabolites, in this case lipoxygenase derived, but CYP450 metabolites were not investigated. Interestingly, the ARA effect was potentiated by the cyclooxygenase inhibitor indomethacin which provides a possible explanation for the antihyperalgesic synergy of coadministration of sEHI with coxibs in vivo .
The recent demonstration that EpFA modulate endoplasmic reticulum stress (ER stress) is another mechanism of antinociception in chronic pain states. ER stress and the unfolded protein response are regulatory mechanisms leading to apoptosis and cell death when overwhelmed. In the peripheral nervous system of diabetic rats sEHI lowered activated ER stress responses including decreasing cleaved activating transcription factor 6 (ATF6) expression and ATF4 mRNA in the sciatic nerves . sEHI also blocked phosphorylation of the three major ER stress sensors PERK, eIF2a and IRE1a. sEHI down-regulated ATF4 and ATF6 mRNA in hepatic fibrosis (Harris et al., 2015) and deletion of sEH is correlated with decreased mitogen-activated protein kinases p38 and c-jun NH2-terminal kinase (JNK) activation in acute pancreatitis (Bettaieb et al., 2014) . JNK and p38 are stress activated and have roles in the generation of pain sensitivity (Purves et al., 2001; Ji et al., 2009 ). Given these several modes of action, more evidence is required to determine if modulating opioid signalling is a primary mechanism of EpFA-mediated analgesia. However, it does suggest spinal/supraspinal modulation of nociception by EpFA in chronic pain states.
Interestingly, there was an apparent induced CPP with t-TUCB over TPPU in neuropathic sEH null mice. Recently we reported that t-TUCB is a far more potent inhibitor of fatty acid amide hydrolase (FAAH) than TPPU (Sasso et al., 2015) . Nevertheless, t-TUCB had no effect when tested in non-diabetic sEH null mice (Wagner et al., 2014b) , which concurs with evidence that the sEHI are not active in the absence of pain Wagner et al., 2013) . Ultimately these results in diabetic mice (wild type and sEH null) support that the analgesia is dependent on EpFA and sEHI, unlike opioids, lack reward and are highly effective in neuropathic pain models.
Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article: Figure S1 . Analysis of the methyl EDP regioisomeric mixture. Figure S2 . The sEH inhibitor t-TUCB was quantified and approaches steady state with repeated dosing with favourable pharmacokinetics over the training period of the CPP assay. Figure S3 . Low-dose t-TUCB, EDPs alone or enriched DHA oil + t-TUCB do not induce a significant CPP response. Figure S4 . The enzymatic scheme for docosahexaenoic acid (DHA).
